Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers

Pharmacogenetics and Genomics

Volumn 24, Issue 1, 2014, Pages 35-42

  Kim, Kyoung Ah ^a   Joo, Hyun Jin ^a   Lee, Hae Mi ^a   Park, Ji Young ^a  

^a College of Medicine   (South Korea)

Author keywords

ABCB1; CYP3A5; P glycoprotein; Pharmacokinetics; Quetiapine

Indexed keywords

CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; QUETIAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP3A; DIBENZOTHIAZEPINES; GENE FREQUENCY; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84891025545     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000020     Document Type: Article

References (39)

1. Thase ME, Macfadden W,Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a doubleblind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609. (Pubitemid 44772737)
2. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA,Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360. (Pubitemid 40905587)
3. El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, doubleblind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917-932.
4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009; 70: 540-549.
5. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522.
6. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163-169. (Pubitemid 34595435)
7. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004; 56: 967-975. (Pubitemid 39140051)
8. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47-54. (Pubitemid 34311087)
9. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV- 1 protease inhibitors. J Clin Invest 1998; 101: 289-294. (Pubitemid 28067324)
10. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 2012; 27: 85-105.
11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473-3478. (Pubitemid 30183327)
12. Song P, Lamba JK, Zhang L, Schuetz E, Shukla N, Meibohm B, et al. G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression. J Clin Pharmacol 2006; 46: 373-379. (Pubitemid 43260324)
13. Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ, et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009; 29: 272-277.
14. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007; 7: 154-179. (Pubitemid 46794925)
15. Bakken GV, Rudberg I, Christensen H, Molden E, Refsum H, Hermann M. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009; 37: 254-258.
16. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69. (Pubitemid 43381238)
17. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391. (Pubitemid 32268418)
18. Hustert E, Haberl M, Burk O,Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779. (Pubitemid 33151512)
19. Kim KA, Song WK, Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 2009; 86: 511-518.
20. Lotsch J, Skarke C, Geisslinger G. Simultaneous screening for three mutations in the ABCB1 gene. Genomics 2003; 82: 503-510. (Pubitemid 37239026)
21. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006; 187: 415-423. (Pubitemid 44200513)
22. Gonzalez-Vacarezza N, Dorado P, Penas-Lledo EM, Farinas H, Estevez- Carrizo FE, Llerena A. MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers. Drug Metabol Drug Interact 2013; 28: 163-166.
23. Nikisch G, Baumann P, Oneda B, Kiessling B,Weisser H, Mathe AA, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2011; 25: 896-907.
24. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7: 415-419. (Pubitemid 39648071)
25. Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav 2012; 102: 312-320.
26. Moons T, de Roo M, Claes S, Dom G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics 2011; 12: 1193-1211.
27. Rahi M, Heikkinen T, Hartter S, Hakkola J, Hakala K, Wallerman O, et al. Placental transfer of quetiapine in relation to P-glycoprotein activity. J Psychopharmacol 2007; 21: 751-756. (Pubitemid 47437915)
28. Li KY, Li X, Cheng ZN, Zhang BK, Peng WX, Li HD. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol 2005; 60: 791-795. (Pubitemid 40394573)
29. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891. (Pubitemid 34815417)
30. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006; 2: 171-182. (Pubitemid 46372363)
31. Park PW, Seo YH, Ahn JY, Kim KA, Park JY. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34: 569-574.
32. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47: 87-93.
33. Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80: 646-656. (Pubitemid 44920220)
34. Park JY, Kim KA, Park PW, Lee OJ, Kang DK, Shon JH, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006; 79: 590-599.
35. Sparshatt A, Taylor D, Patel MX, Kapur S. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 2011; 72: 1108-1123.
36. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011; 33: 222-226.
37. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-339. (Pubitemid 27145435)
38. Jensen NH, Rodriguiz RM, Caron MG,Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008; 33: 2303-2312.
39. Rasmussen H, Ebdrup BH, Aggernaes B, Lublin H, Oranje B, Pinborg LH, et al. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia. J Clin Psychopharmacol 2013; 33: 266-269.